Skip to main content

An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.

Publication ,  Conference
Sathornsumetee, S; Reardon, DA; Quinn, JA; Rich, JN; Vredenburgh, JJ; Desjardins, A; Gururangan, S; Egorin, M; Salvado, A; Friedman, HS
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

72S / 72S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sathornsumetee, S., Reardon, D. A., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Desjardins, A., … Friedman, H. S. (2006). An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 72S-72S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Sathornsumetee, S., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Gururangan, M. Egorin, A. Salvado, and H. S. Friedman. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.” In JOURNAL OF CLINICAL ONCOLOGY, 24:72S-72S. AMER SOC CLINICAL ONCOLOGY, 2006.
Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, et al. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 72S-72S.
Sathornsumetee, S., et al. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 72S-72S.
Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 72S-72S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

72S / 72S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences